Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Juan Londono

Cardiovascular Disease Miami Beach, FL Medical Doctor

NPI 1871595645 CMS profile 312204

4300 Alton Road, Suite 2050, Miami Beach, FL 33140

Open in the dashboard

General payments

$3,376

142 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,285,793 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Juan Londono of Miami Beach, FL is reported in the CMS Open Payments database as having received $3,376 across 142 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,285,793 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 60th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $432 5
2024 General $37 2
2023 General $325 14
2022 General $585 29
2021 General $714 32
2020 General $477 22
2019 General $806 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Juan Londono
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Juan Londono were reported at $432. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Juan Londono Cardiovascular Disease median Middle half National median
2019 $806 $450 $127–$1,392 $163
2020 $477 $242 $77–$751 $114
2021 $714 $335 $101–$1,037 $132
2022 $585 $395 $121–$1,211 $149
2023 $325 $443 $136–$1,283 $160
2024 $37 $450 $136–$1,323 $164
2025 $432 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $690 9 payments
  2. E.R. Squibb & Sons, L.L.C. $386 20 payments
  3. Janssen Pharmaceuticals, Inc $318 18 payments
  4. Medtronic Vascular, Inc. $250 4 payments
  5. AstraZeneca Pharmaceuticals LP $215 10 payments
  6. Novartis Pharmaceuticals Corporation $215 12 payments
  7. Pfizer Inc. $195 11 payments
  8. Amarin Pharma Inc. $184 10 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $133 6 payments
  10. Sanofi-Aventis U.S. LLC $112 6 payments
  11. Other $676 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,192 137 payments
  2. Education $133 4 payments
  3. Debt forgiveness $51 1 payment
Products named General payments · program years 2019–2025
  1. Micra Pacemakers $561 5 payments
  2. ELIQUIS Cardiovascular $371 19 payments
  3. XARELTO $318 18 payments
  4. ELIQUIS Cardiovascular;Metabolic Disease $195 11 payments
  5. MICRA Pacemakers $177 3 payments
  6. BRILINTA $171 7 payments
  7. Vascepa $153 8 payments
  8. JARDIANCE $133 6 payments
  9. ENTRESTO $110 6 payments
  10. VYNDAQEL $104 6 payments
  11. Other $1,451 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

2,131

Median for Cardiology: 2,533

Drug cost

$310,349

Median for Cardiology: $485,213

Branded share of claims

29.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 86 $100,385
Entresto Sacubitril/Valsartan Brand 62 $63,494
Repatha Sureclick Evolocumab Brand 33 $26,928
Vascepa Icosapent Ethyl Brand 38 $21,764
Xarelto Rivaroxaban Brand 19 $21,566
Brilinta Ticagrelor Brand 14 $17,678
Repatha Syringe Evolocumab Brand 29 $16,316
Jardiance Empagliflozin Brand 13 $12,048
Ranolazine Er Ranolazine Brand 54 $7,570
Icosapent Ethyl Generic 12 $3,237

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$320,721

Of which drugs: $1,385

Medicare patients

130

Average age 76

Services billed

1,689

74 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 48%
Diabetes 40%
Depression 25%
Chronic kidney disease 24%
Osteoporosis 23%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 71 281 $1,385

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $21
$21 86 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $8
$8 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $8
$8 62 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

142 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record